OncoMatch/Clinical Trials/NCT06585527
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma
Is NCT06585527 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies TS-2021 for glioblastoma multiforme.
Treatment: TS-2021 — The goal of this clinical trial is to evaluate the safety and efficacy of oncolytic virus TS-2021 in the treatment of recurrent malignant glioma.About 30 eligible participants with recurrent malignant glioma will : * Be intratumoral injected the TS-2021 oncolytic virus to study its safety and efficacy. * Be followed for 1 year after the injection to complete imaging studies, neurological function tests, and report adverse events. Using the data obtained during the follow-up period, researchers will conduct statistical analyses and evaluate the safety and efficacy of oncolytic virus TS-2021.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Disease stage
Grade: high-grade
The patient had a recurrence of supratentorial high-grade glioma.
Demographics
Prior therapy
Must have received: surgery — initial
After the initial surgery, the imaging showed that the tumor was completely removed, followed by conventional radiotherapy or (and) chemotherapy
Must have received: radiotherapy — initial
followed by conventional radiotherapy or (and) chemotherapy
Must have received: chemotherapy — initial
followed by conventional radiotherapy or (and) chemotherapy
Lab requirements
Blood counts
neutrophil absolute value ≥ 1,500/mm3, hemoglobin ≥10 g/dl, platelet count ≥100,000/mm3
Kidney function
serum creatinine ≤1.5×uln
Liver function
total bilirubin level ≤1.5×uln, glutamic pyruvic transaminase/glutamic oxalacetic transaminase ≤ 2.5× uln
Cardiac function
the heart function was normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06585527 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received surgery and radiotherapy.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages